Early experience with intrasphincteric botulinium toxin in the treatment of achalasia

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 9, 1999, Pages 1221-1225

  Greaves, R R S H ^a   Mulcahy, H E ^a   Patchett, S E ^a   Gorard, D A ^a   Fairclough, P D ^a   Alstead, E M ^a   Farthing, M J G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ESOPHAGUS ACHALASIA; ESOPHAGUS MANOMETRY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SCORING SYSTEM; SYMPTOM; THORAX PAIN; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DISEASE-FREE SURVIVAL; ESOPHAGEAL ACHALASIA; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 0032854379     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00609.x     Document Type: Article

References (31)

1. Katz PO, Achalasia. In: Castell DO, Richter J. Dalton C. eds. Esophageal Motility Testing. New York: Elsevier, 1987: 107-17.
2. Csendes A, Braghetto I, Henriquez A, Cortes C. Late results of a prospective randomised study comparing forceful dilatation and oesophagomyotomy in patients with achalasia. Gut 1989; 30: 299-304.
3. Eckhardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilatation. Gastroenterology 1992: 103; 1732-8.
4. Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 1996; 110: 1410-5.
5. Annese V, Basciani M, Porri F, et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilatation in achalasia. Gastroenterology 1996; 111: 1418-24.
6. Cuilliere C, Ducrotte P, Zerbib F, et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 1997; 41: 87-92.
7. Elston JS. The clinical use of botulinum toxin. Semin Ophthalmol 1988; 3: 249-60.
8. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186-94.
9. Welch RW, Drake ST. Normal lower oesophageal sphineter pressure: a comparison of rapid vs. slow pull through techniques. Gastroenterology 1980; 78: 1446-51.
10. Marion M-H, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 1995; 59: 102-3.
11. Mearin F, Mourelle M, Guarner F, et al. Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal function. Eur J Clin invest 1993; 23: 724-8.
12. Aggestrup S, Uddman R, Sundler F, et al. Lack of vasoactive intestinal peptide nerves in achalasia. Gastroenterology 1983; 84: 924-7.
13. Holloway RH, Dodds WJ, Helm JF, Hogan WJ, Dent J, Arndorfer RC. Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology 1986; 90: 924-9.
14. Mayberry JF, Atkinson M. A study of swallowing difficulties in first degree relatives of patients with achalasia. Thorax 1985; 40: 391-3.
15. Vago AR, Macedo AM, Adad SJ, d'Avila Reis D, Correa-Oliveira R. PCR detection of Trypanosoma cruzi DNA in oesophageal tissues of patients with chronic digestive Chagas' disease. Lancet 1996; 348: 891-2.
16. Jones DB, Mayberry JF, Rhodes J, Munro J. Preliminary report of an association between measles virus and achalasia. J Clin Pathol 1981; 36: 655-7.
17. Robertson CS, Martin BAB, Atkinson MA, Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993; 34: 299-302.
18. Nimawoto H, Okamoto E, Fujimoto J, Takeuchi M, Furuyama J-I, Yamamoto Y. Are human herpes viruses or measles virus associated with esophageal achalasia? Dig Dis Sci 1995; 40: 859-64.
19. Borotto E, Gaudric M, Danel B, et al. Risk factors of oesophageal perforation during pneumatic dilatation for achalasia. Gut 1996; 39: 9-12.
20. Gelfond M, Rozen P, Keren S, Gilat T. Effect of nitrates on LOS pressure in achalasia: a potential therapeutic aid. Gut. 1981; 22: 312-8.
21. Bortolotti M, Labo G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 1981; 80: 39-44.
22. Cocchia G, Bortolotti M, Michetti P, Dodero M, Prospective clinical and manometric study comparing pneumatic dilatation and sublingual nifedipine in the treatment of oesophageal achalasia. Gut 1991; 32: 604-6.
23. Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982; 83: 963-9.
24. Simpson LL. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33: 155-88.
25. DasGupta RR. The structure of botulinum neurotoxin. In: Simpson LL. eds. Botulinum Neurotoxin and Tetanus Toxin. San Diego: Academic Press, 1989; 53-66.
26. Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: nature and preparation for clinical use. Eye 1988; 2: 16-23.
27. Simpson LL. Peripheral actions of the botulinum toxins. In: Simpson LL. eds. Botulinum Neurotoxin and Tetanus Toxin. San Diego: Academic Press, 1989: 153-78.
28. Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. J Roy Soc Med 1992; 85: 524-9.
29. Pasricha PJ, Ravich WJ, Kalloo K. Effects of intrasphincteric botulinum toxin on the lower oesophageal sphincter in piglets. Gastroenterology 1993; 105: 1045-9.
30. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 322: 774-8.
31. Vaczi MF, Richter JE, Wilcox CM, et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut 1999; 44: 231-9.